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Abstract
Statin therapy is regarded as an effective medication to reduce cardiovascular events in
patients at higher risk for future incidence of coronary artery disease. However, very few stud-
ies have been conducted to examine its implementation in non-Western real-world practice.
In this study, we sought to describe statin prescription patterns in relation to patient character-
istics in a Japanese multicenter percutaneous coronary intervention (PCI) registry as a foun-
dation for quality improvement. We studied 15,024 patients that were prospectively enrolled
in the Japan Cardiovascular Database-Keio interhospital Cardiovascular Study Registry from
January 2009 to August 2014. The overall discharge statin non-prescription rate was 15.2%,
without significant interhospital (MOR = 1.01) or annual differences (MOR = 1.13) observed.
Hierarchical multivariable logistic regression analysis accounting for regional differences
revealed that the presence of chronic kidney disease was associated with higher rates of
statin non-prescription (OR 1.87, 95% confidence interval, 1.69–2.08, p value <0.001), and
higher age (per 1-year increase) showed a trend for prescription of low-intensity statin (OR
1.00, 95% confidence interval, 1.00–1.01, p value = 0.045) within the subset of PCI patients
(N = 4,853) enrolled after the year 2011. Our study indicates that patients with chronic kidney
disease and elderlies may be the primary targets for maximizing the beneficial effect of statin
therapy in post PCI patients.
Introduction
Statin therapy is regarded as an essential medication to reduce cardiovascular events through
its blood cholesterol lowering and anti-inflammatory effects. [1] [2–4] While minor
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differences exists for statin initiation thresholds and statin dosing, major society guidelines
such as the American College of Cardiology/American Heart Association (ACC/AHA), [5]
European Society of Cardiology/European Atherosclerosis Society (ESC/EAS),[6] National
Lipid Association (NLA), [7] International Atherosclerosis Society (IAS),[8] and the U.S. Pre-
ventive Services Task Force (USPSTF),[9] describe a common understanding that statins are
indeed effective upon risk reduction of cardiovascular events especially in those who possess
high cardiovascular risk. In the secondary prevention setting, the 2013 ACCF/AHA guideline
for the management of ST-elevation myocardial infarction gave a Class IB recommendation
and the 2014 AHA/ACC guideline for the management of patients with non-ST-elevation
acute coronary syndromes gave a Class IA recommendation for the use of moderate- or high-
intensity statins. [10, 11] In fact, recent studies have provided evidence that higher intensity of
statins do have a greater risk reducing effect compared to lower intensity statins. [12] [13] [14]
Consequently, high or moderate intensity statin therapy at the timing of hospital discharge is
considered an essential quality indicator for hospitals performing percutaneous coronary
intervention (PCI) to established coronary artery disease patients. [15] [16] Despite these high
recommendations, recent studies have suggested that statin underdosing is commonly ob-
served in patients with high-risk profiles [17] [18]. These results indicate an important oppor-
tunity to modify current practice to reduce avoidable cardiovascular events although target
patient or hospital characteristics for statin underdosing remain largely unknown in the real-
world setting. Moreover, few studies have examined the implementation of statin therapy out-
side Western countries.[19, 20] [21]
In this study, we sought to describe prescription patterns of statin therapy after PCI and
identify patient risk factors for statin non-prescription or low-intensity statin prescription in a




We studied 15,024 patients undergoing PCI in the Japan Cardiovascular Database-Keio inter-
hospital Cardiovascular Studies (JCD-KiCS) registry from January 2009 to August 2014. The
JCD-KiCS is a multicenter registry designed to collect clinical variables and outcome data
from patients undergoing PCI. Dedicated clinical research coordinators assigned at each site
enrolled the PCI patients consecutively. The clinical variables and in-hospital outcomes for
the JCD-KiCS were defined in accordance with those specified for CathPCI Registry v4.1
(National Cardiovascular Data Registry (NCDR) in order to enable a direct comparison with
the NCDR CathPCI Registry program. [22] Fifteen hospitals from Tokyo, Tochigi, Saitama,
Chiba, and Kanagawa Prefecture in the Kanto area, Japan participated in this PCI registry. The
participating hospitals were mostly large tertiary care referral centers (more than 200 beds;
N = 12), but also included a few mid-sized satellite hospitals (less than 200 beds; N = 3). The
average annual case-volume was 331 (ranging from 104 to 517) during the study period.
The participating hospitals were instructed to record and register data from consecutive
hospital visits for PCI using an internet-based data collection system. Written informed con-
sent was routinely obtained from patients before undergoing PCI. PCI with any commercially
available coronary device was included. The quality of the data entered in the web-based data
capture system were assured by an automatic validation system and reporting for data com-
pleteness, and through standardized education and training for the dedicated clinical research
coordinators at each site (I.U.). Finally, the collected data were checked for completeness and
internal consistency (S.K., Y.M.).
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The Institutional Review Board of Keio University School of Medicine as well as each par-
ticipating hospital approved the JCD-KiCS registry study protocol. The study was carried out
in accordance with the approved guidelines. Before the launch of the registry, the objectives of
the present study, its social significance, and an abstract were provided for clinical trial regis-
tration with the University hospital Medical Information Network (UMIN), which is recog-
nized by the International Committee of Medical Journal Editors as an “acceptable registry”
according to a statement issued in September 2004 (UMIN R000004736). UMIN is the largest
and most versatile academic network information center for biomedical sciences in the world,
and it is now considered as an indispensable information infrastructure for the Japanese medi-
cal community (http://www.umin.ac.jp/english/whatisumin.htm).
Definitions of key variables
Previous history of CAD was defined as having a previous history of either myocardial infarc-
tion, PCI or CABG. Cardiogenic shock was defined as systolic blood pressure below 90 mmHg
persisting over 30 minutes, the need for inotropes or mechanical circulatory support devices
to maintain a systolic blood pressure of 90 mmHg or end-organ hypoperfusion state. Esti-
mated glomerular filtration rate (eGFR) was calculated using the Modification of Diet in Renal
Disease (MDRD) Study equation [23]. Presence of CKD was defined as an eGFR below 60 mL/
min/1.73 m2. Additional data elements and definitions can be found at www.ncdr.com.
Patient selection and exclusion criteria
First, we compared the baseline demographics of patients discharged with and without statins
(N = 13,057) (Fig 1). Patients with missing baseline data (N = 140), patients with possible vaso-
spastic angina (N = 668), patients who died during the same hospitalization as the PCI proce-
dure (N = 21), and patients with missing discharge statin status (N = 1,138) were excluded
from the analysis (Fig 1 & S1 Table).
Second, within the subgroup of patients with complete statin intensity status (N = 4,853)
(Fig 1) that began after the year 2011 as additional variables, statin intensity was classified
according to the 2013 American College of Cardiology (ACC)/American Heart Association
(AHA) guideline. High intensity statins were defined as atorvastatin 40-80mg/day and rosu-
vastatin 20mg/day, and moderate intensity statins were defined as atorvastatin 10-20mg/day,
rosuvastatin 5-10mg/day, simvastatin 20-40mg/day, pravastatin 40mg/day, lovastatin 40mg/
day, fluvastatin 40mg/day, pitavastatin 2-4mg/day. Any statins below these dosing were classi-
fied as low intensity statins [24].
Statistical analysis
The Student’s t-test or the Wilcoxon rank-sum test was used to compare continuous variables
of those with or without discharge statin at PCI discharge. The Chi-square test or Fisher’s
exact test was used to compare categorical variables, as appropriate. To examine the extent of
practice-level variation in statin use multivariable hierarchical logistic regression models were
constructed to determine the median rate ratio (RR). These were two-level hierarchical models
with the practice modeled as a random effect and patient covariates as fixed effects. [25] [26]
The resulting median odds ratio (MOR) can be interpreted as the likelihood that two random
practices would differ in treating theoretically identical patients with or without statins as well
as treatment with low or moderate to high intensity statins after the PCI procedure. MOR is
always above or equal to 1, with a MOR >1.20 suggesting significant practice-level variation.
In addition, we examined whether patient-level predictors were stronger determinants of
statin treatment than practice-level variation using a hierarchical multilevel logistic regression
Statin use in Japanese PCI patients
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model. We included the following patient characteristic covariates to predict statin non-pre-
scription: age, gender, and previous history of PCI and CKD due to their clinical significance
from previous studies. Similarity, we included the following patient characteristic covariates to
predict low-intensity statin prescription: age, gender, previous history of PCI and cerebrovas-
cular disease due to their clinical significance from previous studies. A p value below 0.05 was
considered to be statistically significant, unless mentioned otherwise in our analysis. All statis-
tical analysis was performed using STATA version 13.1 (http://www.stata.com).
Results
The current study population was consisted of 13,057 PCI patients with a mean age of 68.0 ±
10.9 years, 20.6% female, an average BMI of 24.2 ±3.6, 37.3% with a history of PCI, 5.5% with a
Fig 1. Study population for discharge statin prescription rate.
https://doi.org/10.1371/journal.pone.0182687.g001
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history of CABG and 46.9% presented to the PCI hospital with acute coronary syndrome
(Table 1). Overall, 15.2% (N = 1,983) of the patients did not receive statin therapy at the timing
of discharge. Patients without discharge statins had similar baseline characteristics and CAD
presentation as well as serum cholesterol levels upon admission compared with those who were
on statins, although presence of CKD was frequently observed in the statin non-prescription
group (39.9% vs 26.6%, P value<0.001)(Tables 1 & 2). Discharge prescription rate for other key
medications such as aspirin (98.7% vs 96.1%, P value<0.001), clopidogrel (91.2% vs 86.1%,
P value<0.001), renin angiotensin aldosterone system inhibitors (66.3% vs 57.1%, P value
<0.001) and beta-blockers (70.1% vs 51.0%, P value<0.001) were significantly lower in the
statin non-prescription group while a greater proportion of patients were on warfarin in the
same group (9.6% vs 12.1%, P value<0.001). Statin non-prescription rate ranged from a mini-
mum of 11.9% to a maximum of 18.0% among participating hospitals (MOR = 1.01) (Fig 2) and
a minimum of 14.3% to a maximum of 15.6% among patient registration year (MOR = 1.13).
The second part of our analysis was performed within the subgroup of patients with full
description of statin type and dosing (N = 4,845); 41.5% (N = 2,018) of the patients were on
Table 1. Baseline characteristics of patients with and without discharge statins.
Overall No Statin Statin
N = 13,024 N = 1,983 N = 11,078 P value
Age (mean, SD) 68 ±10.9 68 ±10.6 68.1±10.9 0.91
Female 2557 20.6% 410 21.7% 2147 20.4% 0.23
Body mass index (mean,SD) 24.2 ±3.6 24.1 ±13.5 24.2±3.7 0.42
Medical History
Myocardial infarction 3062 24.6% 452 23.9% 2610 24.9% 0.34
Heart failure 1101 8.9% 170 9.0% 931 8.9% 0.9
PCI 4650 37.3% 695 36.7% 3955 37.6% 0.45
CABG 672 5.5% 96 5.1% 576 5.5% 0.47
Diabetes mellitus 5137 41.9% 800 42.4% 4337 41.5% 0.64
Chronic Kidney Disease 3701 28.3% 781 39.9% 2920 26.6% <0.001
Hemodialysis 578 4.4% 76 4.0% 502 4.8% 0.14
Cerebrovascular disease 1108 8.5% 177 9.4% 931 8.9% 0.51
Peripheral vascular disease 1040 8.0% 163 8.6% 877 8.4% 0.75
Chronic lung disease 381 2.9% 52 2.8% 329 3.1% 0.36
Hypertension 9268 70.9% 1405 74.4% 7863 75.2% 0.44
Smoking 4181 32.0% 624 33.1% 3557 34.1% 0.37
Dyslipidemia 8173 62.5% 1239 65.7% 6934 66.4% 0.56
Family history of CAD 1440 11.0% 223 11.9% 1217 11.8% 0.86
Cancer 487 3.7% 68 3.8% 419 4.1% 0.45
Cardiogenic shock 552 4.2% 86 4.3% 466 4.2% 0.81
Acute coronary syndrome 6022 46.1% 923 46.5% 5099 46.1% 0.3
Discharge medications
Aspirin 12894 98.7% 1912 96.1% 10982 99.1% <0.001
Clopidogrel 11924 91.2% 1712 86.1% 10212 92.2% <0.001
RAAS inhibitor 8659 66.3% 1136 57.1% 7523 67.9% <0.001
Beta-blockers 9166 70.1% 1014 51.0% 8152 73.6% <0.001
Warfarin 1255 9.6% 241 12.1% 1014 9.2% <0.001
Abbreviations: CAD; Coronary artery disease, SD; Standard deviation, PCI; Percutaneous coronary intervention, CABG; Coronary arterial bypass graft,
LDL; Low-density lipoprotein, HDL; High-density lipoprotein, RAAS; Renin angiotensin aldosterone system
https://doi.org/10.1371/journal.pone.0182687.t001
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low-intensity statins and 58.4% were on moderate to high-intensity statins at the timing of dis-
charge (Fig 1 & Table 3). Merely three patients received high-intensity statins within this Japa-
nese study population. Rosuvastatin (46.4%) and atorvastatin (34.7%) were the two most
favorably prescribed brands of statins in this population (Fig 3). Among the participating hos-
pitals with more than a hundred cases registered within this subgroup population, the low-
intensity statin prescription rate ranged from a minimum of 34.7% to a maximum of 52.0%
(MOR = 1.13) (Fig 4) and a minimum of 39.8% to a maximum of 44.2% among patient regis-
tration year after the year 2011 (MOR = 1.12).
Finally, hierarchical multivariable logistic regression analysis accounting for practice vari-
ability revealed that the presence of chronic kidney disease was associated with higher rates of
statin non-prescription (OR 1.87, 95% confidence interval, 1.69–2.08, p value <0.001) after
adjusting for age, previous history of PCI (S2 Table), whereas higher age (per 1-year increase)
was associated with prescription of low-intensity statin (OR 1.00, 95% confidence interval,
1.00–1.01, p value = 0.045) within the previously mentioned subgroup study population after
adjusting for gender, previous history of PCI and presence of CKD (S3 Table).
Discussion
Our current study showed that more than 15% of PCI patients were discharged without statin
therapy despite a strong recommendation from various practice guidelines. Moreover, low-
intensity statins was frequently observed in those who did receive statins at the timing of dis-
charge. The proportion of statin non-prescription and low-intensity statin prescription were
similar across the participating sites and throughout patient enrollment year. These results
suggest that patient characteristics such as the presence of CKD and higher age can be poten-
tial targets to enhance the quality of care for PCI patients in Japan through maximizing statin
therapy.
In our dataset, the overall discharge statin non-prescription rate was comparable or higher
than that reported in previous Western/non-Western databases. Recently, Pokharel et al
reported the current trend of moderate-intensity to high-intensity statin therapy usage in the
United States, before and after the publication of the 2013 ACC/AHA guideline from the
American College of Cardiology National Cardiovascular Data Registry’s Practice Innovation
and Clinical Excellence (PINNACLE) Registry. [27] The authors reported a 67.0% moderate-
intensity to high-intensity statin prescription rate in ASCVD patients despite a strong recom-
mendation in the new guideline. Similarly, Rodriguez et al also described the current statin
prescription status of ASCVD patients treated in the Veterans Affairs health care system from
April 1, 2013, to April 1, 2014 and found that 18.2% did not receive any statins resulting in a
higher mortality rate compared to other patients on low to high intensity statins. [28] In the
Table 2. Lipid profiles of patients with and without discharge statins.
Overall No Statin Statin
N = 13,068 N = 1,990 N = 11,078 P value
Total cholesterol 182±43 178±39 182±43 0.08
LDL 105±37 105±30 105±37 0.95
HDL 47±14 47±14 47±14 0.72
Triglyceride 125 (86–183) 123(86–172) 127(88–186) 0.07
Total cholesterol, LDL, HDL are presented as mean ± standard deviation
Triglyceride is presented as median and first and third quartiles.
Abbreviations: LDL; Low-density lipoprotein, HDL; High-density lipoprotein
https://doi.org/10.1371/journal.pone.0182687.t002
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European nations underutilization of discharge statin therapy has been identified in the
EUROASPIRE IV survey that reported a 9.6% of CHD patients who were not on statins at dis-
charge. [29] In Japan, Natsuaki et al reported from the CREDO-Kyoto registry cohort-2 that
the discharge statin prescription rate was low as 49.0% in patients undergoing coronary revas-
cularization although this data was derived during 2005 to 2007 and may best represent the
current practice in provided in Japan. [30] Similarly, Kaneko et al reported from a single-cen-
ter study that nearly 40% of stable CAD patients did not receive statin therapy upon discharge
and was indeed associated with a higher risk of three-year major cardiovascular events. [31]
Our current data was derived from 2009 to 2014 that is likely to represent current practice pat-
terns and were also collected from various hospitals situated in the neighboring areas of
Tokyo.
Notably, an exceptionally high statin non-prescription rate was observed in CKD patients
of our registry. In fact, the odds of receiving a statin at the timing of discharge were halved
when CKD was present in the current Japanese study. Prescribing a fixed dose of statins in
CKD patient has been controversial since these patients are perceived to be the most vulnera-
ble to experience statin adverse effects especially when receiving higher intensity statins. The
2013 ACC/AHA Guideline on the Treatment of Blood Cholesterol to Reduce Atherosclerotic
Fig 2. Statin non-prescription rate among participating hospitals.
https://doi.org/10.1371/journal.pone.0182687.g002
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Cardiovascular Risk in Adults [15] support the prescription of high-intensity statins therapy in
adults with clinical CVD and CKD if not on hemodialysis. This recommendation is supported
by a prospective observational study and meta-analysis showing the beneficial effect of statin
therapy to reduce fatal cardiovascular events as well as non-fatal cardiovascular events. [32]
[33] [34] On the contrary, a recent study conducted by Acharya et al suggest that statin use is
associated with aggravating effect on renal function, thus it is difficult to conclude whether or
not statin use is effective universally in this population. [35] The local Japan Atherosclerosis
Society Guidelines for Prevention of Atherosclerotic Cardiovascular Diseases 2012 also gives
similar recommendations for using statins in this particular population. [36] As for patients
who are already on hemodialysis, the 2013 ACC/AHA guideline does not give any statements
and the decision is largely left to the physician’s discretion. [24] Interestingly, in our dataset,
hemodialysis patients had a higher statin prescription rate compared to CKD patients not on
hemodialysis although they represent only four percent of the entire cohort. This may be due
to the physician’s belief that hemodialysis patients would tolerate the medication better by
receiving mechanical excretion of drug and metabolites without affecting renal function. The
outcome of this practice pattern is yet to be determined when further long-term outcome data
is available.
Suboptimal dosing of discharge statins is also a problem along with statin non-prescription.
In our study, only 3 (0.1%) patients were prescribed with high-intensity statins while 41.6%
were on low-intensity statins that may lead to cardiovascular events if not titrated up to higher
dosing. Importantly, Rodriguez et al. described that high-intensity statins are indeed associated
with a small but significant survival advantage compared with moderate-intensity statins, even





N = 4,845 N = 2,016 N = 2,837 P value
Age (mean, SD), y 68.1±10.9 68.4±10.9 67.8±11.0 0.05
Female 943 19.40% 403 20.00% 540 19.10% 0.38
Body mass index (mean, SD) 24.2±3.7 24.2±3.7 24.3±3.6 0.14
Medical History
Myocardial infarction 1126 23.20% 475 23.60% 651 23.00% 0.57
Heart failure 391 8.10% 173 8.60% 218 7.70% 0.25
PCI 1721 35.50% 743 36.90% 978 34.60% 0.07
CABG 244 5.00% 112 5.60% 132 4.70% 0.15
Diabetes mellitus 1909 39.30% 812 40.30% 1097 38.80% 0.24
Chronic Kidney Disease 1342 27.70% 561 27.80% 781 27.60% 0.87
Hemodialysis 205 4.20% 90 4.50% 115 4.10% 0.47
Cerebrovascular disease 403 8.30% 186 9.20% 217 7.70% 0.046
Peripheral vascular disease 378 7.80% 167 8.30% 211 7.50% 0.26
Chronic lung disease 145 3.00% 63 3.10% 82 2.90% 0.63
Hypertension 3478 71.70% 1426 70.70% 2052 72.50% 0.27
Smoking 1532 31.60% 625 31.00% 907 32.10% 0.53
Dyslipidemia 3095 63.80% 1263 62.60% 1832 64.80% 0.19
Family history of CAD 512 10.60% 207 10.30% 305 10.80% 0.63
Cardiogenic shock 206 4.20% 85 4.20% 121 4.30% 0.93
Acute coronary syndrome 2272 46.80% 942 46.70% 1330 47.00% 0.83
Abbreviations: CAD; Coronary artery disease, SD; Standard deviation, PCI; Percutaneous coronary intervention, CABG; Coronary arterial bypass graft
https://doi.org/10.1371/journal.pone.0182687.t003
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among older adults. [14] In the current 2013 ACC/AHA guideline, high-intensity statin ther-
apy is recommended in patients with established CAD under the age of 75 and moderate
intensity statins above the age of 75 if tolerated. [24] A study of ACS patients from the Get
With The Guidelines database showed that 38.3% of the population was treated with high
intensity statins as compared with 0.1% in the current Japanese population. [37] However it is
worth mentioning that moderate intensity statins were prescribed in 58.3% of the study popu-
lation with 26.8% of the population aging above 75. There are several factors that could have
influenced cholesterol treatment patterns for post PCI patients in Japan; 1) the solely approved
high-intensity statin in Japan is rosuvastatin given at 20mg per day, 2) higher sensitivity
towards statins in East Asians leading to the anticipation of increased risk for statin intolerance
and 3) relatively large proportion of elderly PCI patients with more comorbidities. East Asians
are recognized to hold a higher risk for statin intolerance especially when additional factors
such as older age, female gender, low BMI and CKD is present. [38, 39] Moreover, since a
larger proportion of Japanese PCI patients are in their eighties or nineties compared to the
Western PCI population, more patients are likely to hold these risks and the number of elderly
Fig 3. Discharge statin intensity and statin type.
https://doi.org/10.1371/journal.pone.0182687.g003
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CAD population is expected to grow over the coming two to three decades in this region of the
world [22, 40]. Since there is no clear-cut answer for statin dosing in elderly patients, more evi-
dence through randomized clinical trials and high quality observational research with a patient
centered, tailored approach is warranted in this unique population. [41]
Recently, two new classes of non-statin blood-lowering medications have been shown to
improve clinical outcomes in addition to maximally tolerated dose of statins; ezetimibe and
proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors.[42–44] These medications
may play a key role in treating patients with familial hypercholesterolemia and those with
statin intolerance despite holding a high CVD risk but the cost associated with these medica-
tions are also a risk that the patient and physician need to take into consideration. Our study
indicates that there is room for improvement to enhance the quality of post PCI care by utiliz-
ing contemporary and cost efficacious resources such as statin therapy. To meet this goal,
elderlies and CKD patients who underwent PCI may be the ideal target to improve care in this
real-world registry.
Fig 4. Low-intensity statin prescription rate among participating hospitals.
https://doi.org/10.1371/journal.pone.0182687.g004
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Limitations
There are several limitations to our current study. First, our study had the inherent limitations
of any nonrandomized observational research. These results are derived from a multicenter
cohort registry that cannot indefinitely clarify the cause and effect relationship between the
exposure of interest and outcomes even after rigorous adjustment for possible confounders.
Second, key factors that may have affected statin non-prescription such as medication status
prior to PCI admission, previous intolerance to statins, statin allergy, patient preferences,
socioeconomic and education level were not collected in this registry although the impact of
socioeconomic status may be smaller compared to other countries with much disparity since
Japan is known to have a relatively large proportion of middle-class income households rein-
forced with a universal health care system. Third, the current registry did not collect details of
post-discharge follow-up clinic, especially data on post-discharge statin initiation or titrations,
however, we believe that the number of these patients are small and do not affect the overall
results shown in our current analysis. Fourth, long-term outcome data on cardiovascular
death or unplanned hospitalization for revascularization were not available in this current
database. Further follow-up data is necessary to evaluate the relationship of discharge statin
non-prescription, dose-intensity and subsequent clinical hard endpoints. Fifth, although eval-
uated within a large prospective multicenter registry, our current data represents the real-
world prescription of statins in Japanese PCI patients and may not be generalizable in Western
countries where the incidence and demographics of coronary artery disease patients differ
largely. However, given the fact that we are still at the dawn of implementing high-intensity
statins after PCI when looking at a global scale, our results may be of value in countries strug-
gling to improve quality of care by targeting patients with high-risk characteristics based on
current/previous cardiology practice.
Conclusions
The findings of this study suggest that discharge statin non-prescription rates following PCI in
a Japanese context are considerably high, especially in those with chronic kidney disease. In
addition, in contrast to the recommendation of using high-intensity statins in established
CAD patients, low-intensity statins prescription was frequently observed in a subgroup of post
PCI patients with complete statin intensity status. Long-term data on the subsequent incidence
of recurrent coronary events as a function of these observed treatment practices is warranted.
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